Estrogen receptor β ligand therapy activates PI3K/Akt/mTOR signaling in oligodendrocytes and promotes remyelination in a mouse model of multiple sclerosis

Neurobiology of Disease

Volumn 56, Issue , 2013, Pages 131-144

  Kumar, Shalini ^b   Patel, Rhusheet ^a   Moore, Spencer ^a   Crawford, Daniel K ^a   Suwanna, Nirut ^b   Mangiardi, Mario ^a   Tiwari Woodruff, Seema K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Axon conduction; Demyelination; Estrogen receptor ligands; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Neuroprotective drug; Oligodendrocytes; Remyelination; Second messenger signaling

Indexed keywords

DIARYLPROPIONITRILE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MAMMALIAN TARGET OF RAPAMYCIN; MYELIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXONAL INJURY; CELL LINEAGE; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; LIGAND BINDING; MOLECULAR SIZE; MOUSE; NERVE CONDUCTION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REMYELINIZATION; SIGNAL TRANSDUCTION;

ANIMALS; BLOTTING, WESTERN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CALPAIN; CASPASE 3; CORPUS CALLOSUM; ELECTROPHYSIOLOGICAL PROCESSES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ESTROGEN RECEPTOR BETA; FEMALE; IMMUNOHISTOCHEMISTRY; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON; MULTIPLE SCLEROSIS; MYELIN SHEATH; NITRILES; OLIGODENDROGLIA; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; POSTURAL BALANCE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; SPINAL CORD; TOR SERINE-THREONINE KINASES;

EID: 84878119767     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.04.005     Document Type: Article

References (62)

1. Aguirre C., Jayaraman A., Pike C., Baudry M. Progesterone inhibits estrogen-mediated neuroprotection against excitotoxicity by down-regulating estrogen receptor-beta. J. Neurochem. 2010, 115:1277-1287.
2. Barres B.A., Jacobson M.D., Schmid R., Sendtner M., Raff M.C. Does oligodendrocyte survival depend on axons?. Curr. Biol. 1993, 3:489-497.
3. Bibollet-Bahena O., Almazan G. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways. J. Neurochem. 2009, 109:1440-1451.
4. Boroojerdi B., Hungs M., Mull M., Topper R., Noth J. Interhemispheric inhibition in patients with multiple sclerosis. Electroencephalogr. Clin. Neurophysiol. 1998, 109:230-237.
5. Brown D.A., Sawchenko P.E. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J. Comp. Neurol. 2007, 502:236-260.
6. Caringella A.M., Di Naro E., Loverro G. Clinical function of estrogen receptors in endometrial cancer. Minerva Ginecol. 2011, 63:495-504.
7. Carson M.J., Behringer R.R., Brinster R.L., McMorris F.A. Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron 1993, 10:729-740.
8. Chesik D., De Keyser J., Wilczak N. Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS. J. Mol. Neurosci. 2008, 35:81-90.
9. Crawford D.K., Mangiardi M., Tiwari-Woodruff S.K. Assaying the functional effects of demyelination and remyelination: revisiting field potential recordings. J. Neurosci. Methods 2009, 182:25-33.
10. Crawford D.K., Mangiardi M., Xia X., Lopez-Valdes H.E., Tiwari-Woodruff S.K. Functional recovery of callosal axons following demyelination: a critical window. Neuroscience 2009, 164:1407-1421.
11. Crawford D.K., Mangiardi M., Song B., Patel R., Du S., Sofroniew M.V., Voskuhl R.R., Tiwari-Woodruff S.K. Oestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination. Brain 2010.
12. Das A., Guyton M.K., Butler J.T., Ray S.K., Banik N.L. Activation of calpain and caspase pathways in demyelination and neurodegeneration in animal model of multiple sclerosis. CNS Neurol. Disord. Drug Targets 2008, 7:313-320.
13. DonCarlos L.L., Azcoitia I., Garcia-Segura L.M. Neuroprotective actions of selective estrogen receptor modulators. Psychoneuroendocrinology 2009, 34(Suppl. 1):S113-S122.
14. Du Y., Fischer T.Z., Clinton-Luke P., Lercher L.D., Dreyfus C.F. Distinct effects of p75 in mediating actions of neurotrophins on basal forebrain oligodendrocytes. Mol. Cell. Neurosci. 2006, 31:366-375.
15. Flores A.I., Narayanan S.P., Morse E.N., Shick H.E., Yin X., Kidd G., Avila R.L., Kirschner D.A., Macklin W.B. Constitutively active Akt induces enhanced myelination in the CNS. J. Neurosci. 2008, 28:7174-7183.
16. Franklin K., Paxinos G. The Mouse Brain: In Stereotaxic Coordinates 2001, Academic Press.
17. Garcia-Segura L.M., Arevalo M.A., Azcoitia I. Interactions of estradiol and insulin-like growth factor-I signalling in the nervous system: new advances. Prog. Brain Res. 2010, 181:251-272.
18. Goebbels S., Oltrogge J.H., Kemper R., Heilmann I., Bormuth I., Wolfer S., Wichert S.P., Mobius W., Liu X., Lappe-Siefke C., Rossner M.J., Groszer M., Suter U., Frahm J., Boretius S., Nave K.A. Elevated phosphatidylinositol 3,4,5-trisphosphate in glia triggers cell-autonomous membrane wrapping and myelination. J. Neurosci. 2010, 30:8953-8964.
19. Guyton M.K., Das A., Samantaray S., Wallace G.C.T., Butler J.T., Ray S.K., Banik N.L. Calpeptin attenuated inflammation, cell death, and axonal damage in animal model of multiple sclerosis. J Neurosci Res 2010, 88:2398-2408.
20. Halbreich U., Lemus C.Z., Lieberman J.A., Parry B., Schiavi R.C. Gonadal hormones, sex and behavior. Psychopharmacol. Bull. 1990, 26:297-301.
21. Harrington E.P., Zhao C., Fancy S.P., Kaing S., Franklin R.J., Rowitch D.H. Oligodendrocyte PTEN is required for myelin and axonal integrity, not remyelination. Ann. Neurol. 2010, 68:703-716.
22. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004, 18:1926-1945.
23. Hernandez-Fonseca K., Massieu L., Garcia de la Cadena S., Guzman C., Camacho-Arroyo I. Neuroprotective role of estradiol against neuronal death induced by glucose deprivation in cultured rat hippocampal neurons. Neuroendocrinology 2012, 96:41-50.
24. Hesse A., Wagner M., Held J., Bruck W., Salinas-Riester G., Hao Z., Waisman A., Kuhlmann T. In toxic demyelination oligodendroglial cell death occurs early and is FAS independent. Neurobiol. Dis. 2010, 37:362-369.
25. Hirahara Y., Matsuda K., Gao W., Arvanitis D.N., Kawata M., Boggs J.M. The localization and non-genomic function of the membrane-associated estrogen receptor in oligodendrocytes. Glia 2009, 57:153-165.
26. Hobom M., Storch M.K., Weissert R., Maier K., Radhakrishnan A., Kramer B., Bahr M., Diem R. Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol. 2004, 14:148-157.
27. Jastrzebski K., Hannan K.M., Tchoubrieva E.B., Hannan R.D., Pearson R.B. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors 2007, 25:209-226.
28. Kumar S., Biancotti J.C., Yamaguchi M., de Vellis J. Combination of growth factors enhances remyelination in a cuprizone-induced demyelination mouse model. Neurochem Res 2006.
29. Liedtke W., Cannella B., Mazzaccaro R.J., Clements J.M., Miller K.M., Wucherpfennig K.W., Gearing A.J., Raine C.S. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann. Neurol. 1998, 44:35-46.
30. MacKenzie-Graham A., Tiwari-Woodruff S.K., Sharma G., Aguilar C., Vo K.T., Strickland L.V., Morales L., Fubara B., Martin M., Jacobs R.E., Johnson G.A., Toga A.W., Voskuhl R.R. Purkinje cell loss in experimental autoimmune encephalomyelitis. Neuroimage 2009, 48:637-651.
31. Mallon B.S., Shick H.E., Kidd G.J., Macklin W.B. Proteolipid promoter activity distinguishes two populations of NG2-positive cells throughout neonatal cortical development. J. Neurosci. 2002, 22:876-885.
32. Mangiardi M., Crawford D.K., Xia X., Du S., Simon-Freeman R., Voskuhl R.R., Tiwari-Woodruff S.K. An animal model of cortical and callosal pathology in multiple sclerosis. Brain Pathol. 2011, 21:263-278.
33. Matejuk A., Bakke A.C., Hopke C., Dwyer J., Vandenbark A.A., Offner H. Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2004, 77:119-126.
34. McEwen B. Estrogen actions throughout the brain. Recent Prog. Horm. Res. 2002, 57:357-384.
35. Meltser I., Tahera Y., Simpson E., Hultcrantz M., Charitidi K., Gustafsson J.A., Canlon B. Estrogen receptor beta protects against acoustic trauma in mice. J. Clin. Invest. 2008, 118:1563-1570.
36. Meyers M.J., Sun J., Carlson K.E., Marriner G.A., Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J. Med. Chem. 2001, 44:4230-4251.
37. Minutolo F., Bertini S., Papi C., Carlson K.E., Katzenellenbogen J.A., Macchia M. Salicylaldoxime moiety as a phenolic "A-Ring" substitute in estrogen receptor ligands. J. Med. Chem. 2001, 44:4288-4291.
38. Narayanan S.P., Flores A.I., Wang F., Macklin W.B. Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J. Neurosci. 2009, 29:6860-6870.
39. Oyola M.G., Portillo W., Reyna A., Foradori C.D., Kudwa A., Hinds L., Handa R.J., Mani S.K. Anxiolytic effects and neuroanatomical targets of estrogen receptor-beta (ERbeta) activation by a selective ERbeta agonist in female mice. Endocrinology 2012, 153:837-846.
40. Ozturk A., Smith S.A., Gordon-Lipkin E.M., Harrison D.M., Shiee N., Pham D.L., Caffo B.S., Calabresi P.A., Reich D.S. MRI of the corpus callosum in multiple sclerosis: association with disability. Mult. Scler. 2010, 16:166-177.
41. Paruthiyil S., Cvoro A., Zhao X., Wu Z., Sui Y., Staub R.E., Baggett S., Herber C.B., Griffin C., Tagliaferri M., Harris H.A., Cohen I., Bjeldanes L.F., Speed T.P., Schaufele F., Leitman D.C. Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists. PLoS One 2009, 4:e6271.
42. Prentice R.L., Manson J.E., Langer R.D., Anderson G.L., Pettinger M., Jackson R.D., Johnson K.C., Kuller L.H., Lane D.S., Wactawski-Wende J., Brzyski R., Allison M., Ockene J., Sarto G., Rossouw J.E. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am. J. Epidemiol. 2009, 170:12-23.
43. Rasmussen S., Wang Y., Kivisakk P., Bronson R.T., Meyer M., Imitola J., Khoury S.J. Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing-remitting experimental autoimmune encephalomyelitis. Brain 2007, 130:2816-2829.
44. Saijo K., Collier J.G., Li A.C., Katzenellenbogen J.A., Glass C.K. An ADIOL-ERbeta-CtBP transrepression pathway negatively regulates microglia-mediated inflammation. Cell 2011, 145:584-595.
45. Sanchez M., Picard N., Sauve K., Tremblay A. Challenging estrogen receptor beta with phosphorylation. Trends Endocrinol. Metab. 2010, 21:104-110.
46. Sohrabji F., Lewis D.K. Estrogen-BDNF interactions: implications for neurodegenerative diseases. Front. Neuroendocrinol. 2006, 27:404-414.
47. Strigard K., Holmdahl R., Olsson T. Oestrogen treatment reduces duration of experimental allergic neuritis in rats and suppresses T cell responses to myelin. Acta Neurol. Scand. 1990, 81:436-442.
48. Thomas P., Pang Y., Filardo E.J., Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005, 146:624-632.
49. Tiwari-Woodruff S., Voskuhl R.R. Neuroprotective and anti-inflammatory effects of estrogen receptor ligand treatment in mice. J. Neurol. Sci. 2009, 286:81-85.
50. Tiwari-Woodruff S., Morales L.B., Lee R., Voskuhl R.R. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:14813-14818.
51. Tyler W.A., Gangoli N., Gokina P., Kim H.A., Covey M., Levison S.W., Wood T.L. Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J. Neurosci. 2009, 29:6367-6378.
52. Van't Veer A., Du Y., Fischer T.Z., Boetig D.R., Wood M.R., Dreyfus C.F. Brain-derived neurotrophic factor effects on oligodendrocyte progenitors of the basal forebrain are mediated through trkB and the MAP kinase pathway. J. Neurosci. Res. 2009, 87:69-78.
53. Varea O., Arevalo M.A., Garrido J.J., Garcia-Segura L.M., Wandosell F., Mendez P. Interaction of estrogen receptors with insulin-like growth factor-I and Wnt signaling in the nervous system. Steroids 2010, 75:565-569.
54. Vondran M.W., Clinton-Luke P., Honeywell J.Z., Dreyfus C.F. BDNF+/- mice exhibit deficits in oligodendrocyte lineage cells of the basal forebrain. Glia 2010, 58:848-856.
55. VonDran M.W., Singh H., Honeywell J.Z., Dreyfus C.F. Levels of BDNF impact oligodendrocyte lineage cells following a cuprizone lesion. J. Neurosci. 2011, 31:14182-14190.
56. Voskuhl R.R., Peterson R.S., Song B., Ao Y., Morales L.B., Tiwari-Woodruff S., Sofroniew M.V. Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J. Neurosci. 2009, 29:11511-11522.
57. Warlop N.P., Achten E., Debruyne J., Vingerhoets G. Diffusion weighted callosal integrity reflects interhemispheric communication efficiency in multiple sclerosis. Neuropsychologia 2008, 46:2258-2264.
58. Weiser M.J., Handa R.J. Estrogen impairs glucocorticoid dependent negative feedback on the hypothalamic-pituitary-adrenal axis via estrogen receptor alpha within the hypothalamus. Neuroscience 2009, 159:883-895.
59. Wensky A.K., Furtado G.C., Marcondes M.C., Chen S., Manfra D., Lira S.A., Zagzag D., Lafaille J.J. IFN-gamma determines distinct clinical outcomes in autoimmune encephalomyelitis. J. Immunol. 2005, 174:1416-1423.
60. Wu E., Raine C.S. Multiple sclerosis. Interactions between oligodendrocytes and hypertrophic astrocytes and their occurrence in other, nondemyelinating conditions. Lab. Invest. 1992, 67:88-99.
61. Zeger M., Popken G., Zhang J., Xuan S., Lu Q.R., Schwab M.H., Nave K.A., Rowitch D., D'Ercole A.J., Ye P. Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination. Glia 2007, 55:400-411.
62. Ziehn M.O., Avedisian A.A., Tiwari-Woodruff S., Voskuhl R.R. Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE. Lab. Invest. 2010, 90:774-786.